News

coastal-genomics-press-release

Coastal Genomics Technology to Revolutionize DNA Preparation

Vancouver, BC – February 18, 2013 – Coastal Genomics Inc. announced today that it has agreed to an exclusive licensing agreement with the BC Cancer Agency (BCCA) to commercialize a novel liquid handling automation technology to be marketed as the Ranger automated workstation.

The Ranger automated workstation is capable of completely automating the process of agarose gel size selection of DNA fragments for anywhere between 1 and 96 samples in a single run. In lay terms this means that a gold-standard DNA sample preparation method will now be a realistic option for groups with growing throughput demands. This is an important step in the preparation of DNA samples for “next-generation” DNA sequencing used in research and increasingly, for analysis of clinical cancer samples. “The Ranger automated workstation has greatly improved sample preparation at the BCCA Genome Sciences Centre,” says Andy Mungall, the Centre’s Library Core Group Leader. “It’s cost competitive with other methods and provides high quality output – we have been able to efficiently prepare thousands of samples for several major projects.”

Development of the Ranger automated workstation came about in response to a specific need at the BCCA Genome Sciences Centre to automate the process of size selection of samples being prepared for next-gen DNA sequencing research projects. The ability to rapidly respond to this need with an engineering solution was possible because of a series of investments in the last decade by Genome BC and Genome Canada in the BCCA Genome Sciences Centre’s Technology Development Platform. This support for people, training and equipment has allowed the Platform to address specific technology needs in the life science community in a time sensitive manner. At the GSC, the Ranger workstations have processed over 9000 samples since 2010. Commercialization is an important next step as it makes the technology available to the international research and clinical community.

Coastal Genomics plans to bring the technology to the commercial marketplace in summer of 2013. Ranger workstations have been validated to reliably and accurately size select DNA which in turns simplifies DNA preparation for analysis. The Ranger automated workstation will do so at a cost that accommodates high throughput groups involved in DNA sequencing, gene synthesis and cloning.

About Coastal Genomics

Coastal Genomics Inc. develops and markets automated solutions for the sample preparation needs of Life Sciences. Our first product is the Ranger automated workstation, which provides comprehensive automation for agarose gel size selection. We anticipate the technology will be well received by groups that are looking to automate this gold standard technique at a cost that is comparable to the most economical methods of nucleic acid purification.

Coastal Genomics is a privately owned corporation operating in Vancouver, Canada.

About BC Cancer Agency

The BC Cancer Agency, an agency of the Provincial Health Services Authority, is committed to reducing the incidence of cancer, reducing the mortality from cancer, and improving the quality of life of those living with cancer. It provides a comprehensive cancer control program for the people of British Columbia by working with community partners to deliver a range of oncology services, including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation and palliative care. www.bccancer.ca.

About Genome BC

Genome British Columbia is a catalyst for the life sciences cluster on Canada’s West Coast, and manages a cumulative portfolio of over $550M in research projects and science and technology platforms. Working with governments, academia and industry across sectors such as forestry, fisheries, agriculture, environment, bioenergy, mining and human health, the goal of the organization is to generate social and economic benefits for British Columbia and Canada. www.genomebc.ca

Media contact:

Kevin Baillie
info@coastalgenomics.com
(604) 620-1332